NHANES I | 3856 | 35–74 | 139 (22) | 5.82 (1.19) | 36 | 3.9 | 17 | 1843 | 551 | 4.1 |
NHANES II | 3354 | 35–74 | 135 (20) | 5.75 (1.14) | 37 | 5.2 | 14 | 965 | 258 | 2.4 |
Framingham cohort | 2274 | 35–74 | 133 (20) | 5.57 (1.02) | 47 | 4.5 | 19 | 713 | 188 | 3.2 |
Tecumseh community health study | 1257 | 35–74 | 139 (20) | 5.82 (1.07) | 61 | 3.2 | 19 | 416 | 153 | 6.5 |
Honolulu heart program | 7625 | 45–68 | 134 (21) | 5.63 (0.99) | 44 | 9.1 | 20 | 2045 | 293 | 1.2 |
Puerto Rico heart health program |
Urban | 6612 | 35–74 | 134 (23) | 5.30 (1.09) | 41 | 6.4 | 16 | 1152 | 236 | 1.4 |
Rural | 2879 | 35–74 | 128 (22) | 5.05 (1.00) | 50 | 2.2 | 16 | 468 | 78 | 1.0 |
Yugoslavia cardiovascular disease study |
Urban | 3472 | 35–64 | 136 (19) | 5.27 (1.16) | 69 | 1.1 | 17 | 660 | 131 | 2.9 |
Rural | 2868 | 35–62 | 131 (18) | 4.26 (0.91) | 72 | 0.2 | 17 | 642 | 82 | 2.0 |
Scottish collaborative study | 5734 | 35–72 | 134 (18) | 5.88 (1.04) | 55 | 0.5 | 20 | 1578 | 609 | 5.7 |
Renfrew and Paisley study | 6999 | 45–64 | 148 (23) | 5.86 (0.96) | 57 | 1.3 | 16 | 2529 | 994 | 6.0 |
Glostrup cohort | 3844 | 39–71 | 130 (18) | 6.27 (1.18) | 57 | 2.9 | 10 | 489 | 109 | 2.0 |
Norwegian counties study | 24204 | 35–49 | 136 (16) | 6.41 (1.29) | 48 | 0.7 | 17 | 2292 | 753 | 3.2 |
Iceland Reykjavik study | 8151 | 36–74 | 140 (19) | 6.35 (1.06) | 28 | 1.8 | 19 | 2026 | 683 | 3.4 |
Israeli ischemic heart disease study | 9712 | 40–73 | 135 (20) | 5.40 (1.03) | 51 | 4.6 | 20 | 2678 | 816 | 4.1 |
Lipid research clinics follow-up study |
Random sample | 1992 | 35–74 | 126 (18) | 5.43 (0.96) | 36 | 1.4 | 13 | 226 | 74 | 2.3 |
Hyperlipidaemic | 1628 | 35–74 | 129 (17) | 6.29 (1.25) | 37 | 2.0 | 13 | 195 | 71 | 3.0 |
HDFP (regular care) | 2531 | 35–69 | 156 (21) | 6.01 (1.20) | 42 | 6.1 | 8 | 387 | 137 | 4.6 |
MRFIT (usual care) | 6428 | 35–58 | 138 (15) | 6.65 (0.96) | 59 | 2.7 | 11 | 536 | 226 | 3.8 |
Total | 105420 | | | | | | | 21841 | 6442 | |